CD52 — Drug Target
All drugs that target CD52 — marketed and clinical-stage. Includes 4 drug classes acting on this target.
Drug classes
Monoclonal antibody (CD52 antagonist) · monoclonal antibody (CD52-directed) · Monoclonal antibody · Monoclonal antibody and purine analog
Marketed (2)
- Alemtuzumab (GZ402673) · Genzyme, a Sanofi Company · Monoclonal antibody (CD52 antagonist) · Immunology / Hematology
Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion. - Alemtuzumab infusion · Johns Hopkins University · monoclonal antibody (CD52-directed) · Immunology / Oncology
Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion of T and B cells.
Phase 3 pipeline (1)
- MabCampath-1h · University of British Columbia · Monoclonal antibody (CD52 antagonist) · Oncology, Immunology
MabCampath-1h is a humanized monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Phase 2 pipeline (2)
- Campath Purged Non-myeloablative ASCT · David Rizzieri, MD · Monoclonal antibody · Oncology
Campath (Alemtuzumab) is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes. - Alemtuzumab plus Fludarabine · Genzyme, a Sanofi Company · Monoclonal antibody and purine analog · Oncology
Alemtuzumab is a monoclonal antibody targeting CD52, a protein found on the surface of mature lymphocytes. Fludarabine is a purine analog that inhibits DNA synthesis.
Phase 1 pipeline (2)
- Alemtuzumab s.c. · German CLL Study Group · Monoclonal antibody · Oncology
CD52-targeting monoclonal antibody - Alemtuzumab i.v. · German CLL Study Group · Monoclonal antibody · Oncology
CD52 is a surface protein on mature lymphocytes; Alemtuzumab binds to CD52 and induces cell death.